Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer

Key Inclusion Criteria:

Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
Histologically-confirmed epithelial ovarian cancer (EOC), fallopian tube carcinoma (FTC) or primary peritoneal carcinomas (PPC).
Platinum-resistant recurrent (disease progression ≤6 months after the most recent platinum-based treatment regimen (date calculated from the last administered dose of platinum) or the participant is no longer able to receive.

or declined treatment with platinum-based chemotherapy.

Progression with standard of care therapies, including platinum-based therapies, poly ADP ribose polymerase (PARP) inhibitors or bevacizumab in the platinum-sensitive setting or intolerability to such therapies or patient refusal
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Adequate organ and hematologic function
No more than four prior treatment regimens for platinum-resistant disease
All adverse events from prior treatment must be the Common Terminology Criteria for Adverse Events (NCI CTCAE) v5 Grade ≤ 1, except alopecia and stable neuropathy, which must have resolved to Grade ≤ 2 or baseline.

Key Exclusion Criteria:

Platinum-refractory disease (defined as progression on or within 3 months of completing primary first-line platinum-based treatment)
Non-epithelial histology, including malignant mixed Mullerian tumors
Ovarian tumors with low malignant potential (i.e., borderline tumors), low grade serous ovarian cancer or carcinosarcoma
History of acute coronary syndromes.
History of or current Class II, III, or IV heart failure.
History or evidence of known central nervous system (CNS) metastases or carcinomatous meningitis.
Significant bleeding disorders, vasculitis or a significant bleeding episode from the Gastrointestinal (GI) tract.
History of severe hypersensitivity reactions to antibodies.
Systemic steroid therapy.
History or autoimmune disease that has required systemic treatment with disease-modifying agents, corticosteroids, or immunosuppressive drugs.
Prior organ transplantation including allogenic or autologous stem cell transplantation
Prior treatment with anti-cluster of differentiation 47 (CD47) or anti-SIRPα therapy.